Eventide Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

Eventide Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3M	Buy	954,768 +1,317	+0.1%	+$11.9K	0.14%	153
2026 Q1	$12.1M	Buy	953,451 +1,080	+0.1%	+$12.3K	0.2%	128
2025 Q4	$7.79M	Buy	952,371 +864	+0.1%	+$9.95K	0.12%	154
2025 Q3	$11.4M	Buy	951,507 +74	+0%	+$779	0.19%	123
2025 Q2	$9.66M	Buy	+951,433	New	+$6.39M	0.17%	128
2021 Q4	–	Sell	-724,972	Closed	-$15.2M	–	155
2021 Q3	$15.2M	Sell	724,972 -151,976	-17%	-$3.08M	0.2%	114
2021 Q2	$15.5M	Buy	876,948 +446,948	+104%	+$9.79M	0.21%	105
2021 Q1	$10.5M	Hold	430,000	–	–	0.16%	116
2020 Q4	$14.6M	Buy	+430,000	New	+$12.3M	0.22%	100

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Eventide Asset Management's ORIC Position: Q2 2026 in Review

Eventide Asset Management increased its Oric Pharmaceuticals (ORIC) stake by 0.14% in Q2 2026, buying an estimated $11.9K and bringing the position to 954,768 shares worth $10.3M. The position accounts for 0.14% of the portfolio, ranked #153.

Eventide Asset Management first reported a position in ORIC in Q4 2020 and has held it in 9 quarters since. The position peaked at $15.5M in Q2 2021. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

Eventide Asset Management held 954,768 shares of Oric Pharmaceuticals worth $10.3M as of Q2 2026.
Eventide Asset Management bought 1,317 Oric Pharmaceuticals shares in Q2 2026, an estimated $11.9K.
Oric Pharmaceuticals made up 0.14% of Eventide Asset Management's portfolio in Q2 2026, its #153 holding.
Eventide Asset Management first reported a position in Oric Pharmaceuticals in Q4 2020 and has held it in 9 quarters since.
Eventide Asset Management's Oric Pharmaceuticals position peaked at $15.5M in Q2 2021.
181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.